EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 32 / No 3 (Mars 2016) Med Sci (Paris), 32 3 (2016) 253-259 References
Free Access
Issue
Med Sci (Paris)
Volume 32, Number 3, Mars 2016
Page(s) 253 - 259
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20163203009
Published online 23 March 2016
  1. Marrakchi S, Guigue P, Renshaw BR, et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011 ; 365 : 620–628. [CrossRef] [PubMed] [Google Scholar]
  2. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol 2004 ; 9 : 136–139. [CrossRef] [Google Scholar]
  3. Dubertret L, Mrowietz U, Ranki A, et al. European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006 ; 155 : 729–736. [CrossRef] [PubMed] [Google Scholar]
  4. Acosta-Rodriguez EV, Rivino L, Geginat J, et al. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat Immunol 2007 ; 8 : 639–646. [CrossRef] [PubMed] [Google Scholar]
  5. Leung-Theung-Long S, Guerder S. Les cellules Th17 cells, une nouvelle population de cellules T CD4 effectrices pro-inflammatoires. Med Sci (Paris) 2008 ; 24 : 972–976. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Yssel H, Bensussan A. Existe-t-il dans la peau une nouvelle population lymphocytaire Th22 distincte des lymphocytes Th17 ? Med Sci (Paris) 2010 ; 26 : 12–14. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  7. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006 ; 441 : 235–238. [CrossRef] [PubMed] [Google Scholar]
  8. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003 ; 278 : 1910–1914. [CrossRef] [PubMed] [Google Scholar]
  9. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005 ; 201 : 233–240. [CrossRef] [PubMed] [Google Scholar]
  10. Ma HL, Liang S, Li J, et al. IL-22 is required for Th17 cell-mediated pathology in a mouse model of psoriasis-like skin inflammation. J Clin Invest 2008 ; 118 : 597–607. [PubMed] [Google Scholar]
  11. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008 ; 371 : 1665–1674. [CrossRef] [PubMed] [Google Scholar]
  12. Krueger JG, Ferris LK, Menter A, et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2015 ; 136 : 116–124.e7. [CrossRef] [PubMed] [Google Scholar]
  13. Papp K, Thaçi D, Reich K, et al. Tildrakizumab (MK-3222), an anti- IL-23p19 monoclonal antibody, improves psoriasis in a phase 2b randomized placebo-controlled trial. Br J Dermatol 2015 ; 173 : 930–939. [CrossRef] [PubMed] [Google Scholar]
  14. Kopp T, Riedl E, Bangert C, et al. Clinical improvement in psoriasis with specific targeting of interleukin-23. Nature 2015 ; 521 : 222–226. [CrossRef] [PubMed] [Google Scholar]
  15. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006 ; 36 : 1309–1323. [CrossRef] [PubMed] [Google Scholar]
  16. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007 ; 445 : 648–651. [CrossRef] [PubMed] [Google Scholar]
  17. Papp KA, Langley RG, Sigurgeirsson B, et al. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013 ; 168 : 412–421. [CrossRef] [PubMed] [Google Scholar]
  18. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012 ; 366 : 1190–1199. [CrossRef] [PubMed] [Google Scholar]
  19. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin-17-receptor antibody for psoriasis. N Engl J Med 2012 ; 366 : 1181–1189. [CrossRef] [PubMed] [Google Scholar]
  20. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-α production. J Exp Med 2005 ; 202 : 135–143. [CrossRef] [PubMed] [Google Scholar]
  21. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol 2008 ; 128 : 1207–1211. [CrossRef] [PubMed] [Google Scholar]
  22. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity 2000 ; 13 : 715–725. [CrossRef] [PubMed] [Google Scholar]
  23. Cua DJ, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 2003 ; 421 : 744–748. [CrossRef] [PubMed] [Google Scholar]
  24. Yawalkar N, Karlen S, Hunger R, et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998 ; 111 : 1053–1057. [CrossRef] [PubMed] [Google Scholar]
  25. Bruch-Gerharz D, Fehsel K, Suschek C, et al. A proinflammatory activity of interleukin 8 in human skin: expression of the inducible nitric oxide synthase in psoriatic lesions and cultured keratinocytes. J Exp Med 1996 ; 184 : 2007–2012. [CrossRef] [PubMed] [Google Scholar]
  26. Goebeler M, Toksoy A, Spandau U, et al. The C-X-C chemokine Mig is highly expressed in the papillae of psoriatic lesions. J Pathol 1998 ; 184 : 89–95. [CrossRef] [PubMed] [Google Scholar]
  27. Gottlieb AB, Luster AD, Posnett DN, Carter DM. Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques. J Exp Med 1988 ; 168 : 941–948. [CrossRef] [PubMed] [Google Scholar]
  28. Griffiths CE, Voorhees JJ, Nickoloff BJ. Characterization of intercellular adhesion molecule-1 and HLA-DR expression in normal and inflamed skin: modulation by recombinant gamma interferon and tumor necrosis factor. J Am Acad Dermatol 1989 ; 20 : 617–629. [CrossRef] [PubMed] [Google Scholar]
  29. Lemster BH, Carroll PB, Rilo HR, et al. IL-8/IL-8 receptor expression in psoriasis and the response to systemic tacrolimus (FK506) therapy. Clin Exp Immunol 1995 ; 99 : 148–154. [CrossRef] [PubMed] [Google Scholar]
  30. Groves RW, Ross EL, Barker JN, MacDonald DM. Vascular cell adhesion molecule-1: expression in normal and diseased skin and regulation in vivo by interferon gamma. J Am Acad Dermatol 1993 ; 29 : 67–72. [CrossRef] [PubMed] [Google Scholar]
  31. Xia YP, Li B, Hylton D, et al. Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis. Blood 2003 ; 102 : 161–168. [CrossRef] [PubMed] [Google Scholar]
  32. Lee E, Trepicchio WL, Oestreicher JL, et al. Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 2004 ; 199 : 125–130. [CrossRef] [PubMed] [Google Scholar]
  33. Luo J, Wu S-J, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010 ; 402 : 797–812. [CrossRef] [PubMed] [Google Scholar]
  34. Wilson NJ, Boniface K, Chan JR, et al. Development, cytokine profile and function of human interleukin 17-producing helper T cells. Nat Immunol 2007 ; 8 : 950–957. [CrossRef] [PubMed] [Google Scholar]
  35. Segura E, Touzot M, Bohineust A, et al. Human inflammatory dendritic cells induce Th17 cell differentiation. Immunity 2013 ; 38 : 336–348. [CrossRef] [PubMed] [Google Scholar]
  36. Brembilla NC, Montanari E, Truchetet M-E, et al. Th17 cells favor inflammatory responses while inhibiting type I collagen deposition by dermal fibroblasts: differential effects in healthy and systemic sclerosis fibroblasts. Arthritis Res Ther 2013 ; 15 : R151. [CrossRef] [PubMed] [Google Scholar]
  37. Cheung PFY, Wong CK, Lam CWK. Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 2008 ; 180 : 5625–5635. [CrossRef] [PubMed] [Google Scholar]
  38. Schwarzenberger P, Huang W, Ye P, et al. Requirement of endogenous stem cell factor and granulocyte-colony-stimulating factor for IL-17-mediated granulopoiesis. J Immunol 2000 ; 164 : 4783–4789. [CrossRef] [PubMed] [Google Scholar]
  39. Ogura H, Murakami M, Okuyama Y, et al. Interleukin-17 promotes autoimmunity by triggering a positive-feedback loop via interleukin-6 induction. Immunity 2008 ; 29 : 628–636. [CrossRef] [PubMed] [Google Scholar]
  40. Farhi D, Dupin N. Les biothérapies dans le psoriasis. Presse Med 2009 ; 38 : 832–843. [CrossRef] [PubMed] [Google Scholar]
  41. Viguier M, Richette P, Bachelez H, et al. Paradoxical adverse effects of anti-TNF-alpha treatment: onset or exacerbation of cutaneous disorders. Exp Rev Clin Immunol 2009 ; 5 : 421–431. [CrossRef] [Google Scholar]
  42. Tauber M, Beneton N, Reygagne P, et al. Alopecia areata developing during ustekinumab therapy: report of two cases. Eur J Dermatol 2013 ; 23 : 912–913. [PubMed] [Google Scholar]
  43. Tauber M, Buche S, Reygagne P, et al. Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol 2014 ; 70 : 1146–1149. [CrossRef] [PubMed] [Google Scholar]
  44. Shale M, Kanfer E, Panaccione R, Ghosh S. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut 2008 ; 57 : 1639–1641. [CrossRef] [PubMed] [Google Scholar]
  45. Griffiths CEM, Reich K, Lebwohl M, et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 2015 ; 386 : 541–551. [CrossRef] [PubMed] [Google Scholar]
  46. Langley RG, Elewski BE, Lebwohl M, et al. Secukinumab in plaque psoriasis: results of two phase 3 trials. N Engl J Med 2014 ; 371 : 326–338. [CrossRef] [PubMed] [Google Scholar]
  47. Bonnet MC, Bagot M, Bensussan A. Anticorps monoclonaux ciblant l’IL-17A ou son récepteur dans le psoriasis : une nouvelle approche thérapeutique ? Med Sci (Paris) 2012 ; 28 : 1035–1037. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  48. Bachelez H, van de Kerkhof PC, Strohal R, et al. OPT compare investigators. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet 2015 ; 386 : 552–561. [CrossRef] [PubMed] [Google Scholar]
  49. Duhen T, Geiger R, Jarrossay D, et al. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol 2009 ; 10 : 857–863. [CrossRef] [PubMed] [Google Scholar]
  50. Trifari S, Kaplan CD, Tran EH, et al. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009 ; 10 : 864–871. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.